DRA-161

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDRA-161
Drug Alias NameDRA-187a-based SMIP (Emergent)DRA-187a-based SMIP (Trubion Pharmaceuticals)DRACO anti-CD3 therapeuticDRA-161
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsRejection of organ transplantationLatent Autoimmune Diabetes in Adults
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTrubion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTrubion Pharmaceuticals IncEmergent Biosolutions Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationLatent Autoimmune Diabetes in Adults

Other Information

ATC CodeN/A
Related LinksN/A